BioLytical launches rapid HIV and syphilis test in Australia

Biolytical has launched the Insti multiplex HIV-1/2 syphilis antibody test in Australia, offering the fastest dual HIV and syphilis test available. The test, which provides highly accurate results in just 60 seconds, is now included in the Australian Register of Therapeutic Goods, making it available to healthcare professionals nationwide.

A breakthrough in infectious disease screening

The launch of this rapid test supports Australia’s public health initiatives to increase access to early and reliable STI detection. By providing near-instant results, the test helps healthcare professionals diagnose infections faster and connect patients to care without delays.

Robert Mackie, CEO of Biolytical, emphasized the test’s importance:

“Access to fast, reliable rapid testing is critical to eliminating infectious diseases as public health threats. We’re proud to bring our dual HIV-syphilis test to support Australia’s public health initiatives. Expanding access to testing plays a key role in reducing transmission and improving treatment outcomes.”

Why rapid HIV and syphilis testing matters

HIV and syphilis remain significant public health challenges in Australia:

• 722 new HIV cases were reported in 2023, up from 553 in 2022, underscoring the need for increased testing.
• An estimated 30,000 people in Australia are currently living with HIV.
• Syphilis infections were recorded in almost every region last year, reinforcing the urgency for broader screening efforts.
• Both infections can be asymptomatic in early stages, making regular testing essential to prevent further transmission.

How the Insti multiplex test works

The test is designed to be fast, accurate, and easy to use, requiring just a single drop of blood from a fingerstick. Healthcare professionals can administer the test in a variety of clinical and outreach settings, expanding access to at-risk populations.

Key benefits include:

• Results in just 60 seconds – the fastest dual HIV/syphilis test available.
• Industry-leading accuracy, ensuring reliable diagnoses.
• Portable and shelf-stable, making it ideal for both clinics and community outreach programs.
• Supports immediate patient engagement, helping individuals access treatment quickly.

Where to access the test

The Insti multiplex HIV-1/2 syphilis antibody test is now available for professional use across Australia. Healthcare providers can contact Biolytical or authorized distributors for purchasing details.

A new era in STI screening

David Weaver, VP of commercial at Biolytical, highlighted the test’s impact:

“With rapid results for both HIV and syphilis, this test helps healthcare professionals diagnose infections faster and connect patients to care sooner. By simplifying the screening process and reducing delays, we are improving health outcomes across Australia.”

Biolytical’s global commitment to public health

Manufactured under strict quality standards, the Insti multiplex test is already widely used in Canada and Europe, supporting global efforts to expand access to rapid testing. With its latest entry into Australia, Biolytical is strengthening its mission to provide fast, accurate, and reliable infectious disease screening worldwide.

For more information, visit Biolytical’s official website.